Brexu-cel for patients with R/R B-ALL: 4-year follow-up from the ZUMA-3 trial

The median overall survival (OS) was 25.6 and 47.0 months for all phase I and phase II treated patients (n = 78), and patients who achieved a complete response (CR) or CR with incomplete count recovery (n = 57), respectively. 

Median OS was similar for all treated patients with that across various subgroups, including for patients aged <26 years (n = 15; 23.2 months), aged ≥26 years (n = 63; 26.0 months), and patients with ≥2 prior lines of therapy (n = 63; 25.4 months), and was higher in patients with 1 prior line of therapy (n = 15; 60.4 months). 

Among patients with ≥2 prior lines of therapy, patients with prior blinatumomab (n = 37) had a lower median OS vs those without (n = 26; 16.1 vs 47.0 months), and among responders, patients who did not proceed to subsequent allogeneic hematopoietic stem cell transplantation (allo-HSCT; n = 43) had a higher median OS than those who did (n = 14; 60.4 vs 36.3 months). 

The 48-month OS rate was 40% in all treated patients and was similar across most subgroups but lower in patients with prior blinatumomab (n = 38; 24%) and prior inotuzumab (n = 17; 21%) and higher in patients without prior blinatumomab (n = 38; 55%) and with 1 prior line of therapy (57%). 

No new safety signals were observed.